High PD-L1 expression (>50%) and TMB (>10 mutations/Mb) are associated with better immunotherapy outcomes, seen in only 20–30% of pancreatic cancer patients (4, 19, 23). This evidence concerns the gene CD274 and familial pancreatic carcinoma.